OvaSure Guidance, June 4, 2009

The Society of Gynecologic Oncologists has issued a position statement on a new ovarian cancer screening test called OvaSure™. The Foundation for Women’s Cancer is sharing this statement with you as a Guidance to Women.

We all share the goal of early detection of ovarian cancer, but the OvaSure™ test has not undergone the rigorous clinical trials testing needed to demonstrate its safety and efficacy. For a screening test such as this to be considered effective, a clinical trial must demonstrate a reduction in deaths from ovarian cancer in a population of women evaluated with the test.

You might ask what is the harm in endorsing any test that might help reduce deaths from ovarian cancer? The potential harm comes from several possible problems including: 1) false reassurance from a negative test; 2) the possibility of unnecessary surgeries; and 3) the significant stress and anxiety that may come from a false positive test.

We all look forward to the day when a proven screening test is available, unfortunately we aren’t there yet. Please distribute this attached SGO statement as you feel appropriate.

Spotlight

Hear from Dr. Anil Sood, the Foundation’s Research Chairman, and Carol Brown, 2014 SGO Program Chair, about research of interest to women and the public presented at the 2014 SGO Annual Meeting on Women’s Cancer. Watch the video

Awareness

A new SGO Clinical Practice Statement states women diagnosed with epithelial ovarian, tubal, and peritoneal cancers should be considered for genetic counseling and testing, even in the absence of a family history.

Education

The next Gynecologic Cancer Survivors Course Friday, May 2, 2014 in Long Island, NY. For more information on courses, click here.